

BONE THERAPEUTICS
Public limited liability company
Rue Granbonpré 11, Building H
1435 Mont-Saint-Guibert
RPM : Brabant Wallon
VAT: 0882.015.654

(the "Company")

**INFORMATION ON SHAREHOLDERS' RIGHTS IN ACCORDANCE WITH ARTICLES 7:130
AND 7:139 OF THE BELGIAN CODE ON COMPANIES AND ASSOCIATIONS AT THE
EXTRAORDINARY GENERAL MEETING TO BE HELD ON 5 OCTOBER 2022 FROM 2:00 P.M.
(BELGIAN TIME), AVENUE LLOYD GEORGE 11, 1000 BRUSSELS**

**1. RIGHT OF SHAREHOLDERS TO PLACE ITEMS ON THE AGENDA AND TO SUBMIT
PROPOSALS FOR DECISIONS**

In accordance with article 7:130 of the Belgian Code on companies and associations, one or more shareholders who together hold at least 3% of the capital may request the inclusion of matters to be dealt with on the agenda of the extraordinary general meeting of shareholders, as well as submit proposals for resolutions regarding matters to be dealt with that have been included or are to be included on the agenda.

The shareholder(s) exercising this right must, in order for their request to be dealt with at the extraordinary general meeting, fulfil the following two conditions:

- prove that they hold the percentage set out above at the date of their request (either with a certificate showing the registration of the corresponding shares in the Company's share register, or with a certificate delivered by the licensed account holder or the settlement institution certifying the registration in their name of the corresponding number of dematerialised shares); and
- still be shareholder(s) above the 3% threshold at the record date (on **21 September 2022** at midnight (Belgian time)).

Shareholders may then exercise their right by submitting (i) the draft new items for the agenda, and/or (ii) the draft proposals for resolution to be reflected in the agenda by e-mail to generalassembly@bonetherapeutics.com, by fax to +32 71 12 10 01 or by mail to the attention of Bone Therapeutics, Mr Benjamin D'Haese, Rue Granbonpré 11, Building H, 1435 Mont-Saint-Guibert, Belgium, on **13 September 2022** at the latest. The Company will acknowledge receipt of requests made by e-mail, fax or mail to the address indicated by the shareholder within 48 hours of such receipt.

The Company will publish the revised agenda, on **20 September 2022** at the latest (on the website of the Company at the address www.bonetherapeutics.com, in the Belgian State Gazette and in the press) if one or more requests to add new items or proposals for decisions to the agenda have been validly received within the abovementioned period.

The *ad hoc* proxy form with the items to be dealt with and/or the proposals for decisions will be made available on the website of the Company at the address www.bonetherapeutics.com, at the same time as the publication of the revised agenda, i.e. on **20 September 2022** at the latest.

However, proxies notified to the Company before the publication of a revised agenda shall remain valid for the items of the agenda they cover. As an exception to the above, for items of the agenda which are the subject

of proposals for new resolutions submitted pursuant to article 7:130 of the Belgian Code on companies and associations, the proxy holder may, during the general meeting, deviate from any instructions given by the proxy grantor if the execution of these instructions would prejudice the interests of the proxy grantor. The proxy holder must inform the proxy grantor of this. The proxy must indicate whether the proxy holder is entitled to vote on the new items of the agenda or whether the proxy holder should abstain.

2. RIGHT OF SHAREHOLDERS TO ASK QUESTIONS IN WRITING

In accordance with article 7:139 of the Belgian Code on companies and associations, shareholders have the right to ask questions in writing to the directors prior to the extraordinary general meeting to be held on **5 October 2022**.

The exercise of this right is subject to the following two conditions:

- being a shareholder on the record date (**21 September 2022**, at midnight (Belgian time)); and
- having informed the Company of the intention to participate in the extraordinary general meeting, in accordance with the provisions set out in the convening notice.

These questions can be submitted prior to the extraordinary general meeting by e-mail to generalassembly@bonetherapeutics.com, by fax to +32 71 12 10 01 or by mail to the attention of Bone Therapeutics, Mr Benjamin D'Haese, Rue Granbonpré 11, Building H, 1435 Mont-Saint-Guibert, Belgium. They must be received by the Company no later than 5:00 p.m. (Belgian time) on **29 September 2022**.

During the extraordinary general meeting, the directors shall answer questions raised by the shareholders, in writing before the meeting or orally at the meeting, regarding their reports or the items of the agenda, provided that the disclosure of certain data or facts shall not be prejudicial to the Company or to the confidentiality undertakings given by the Company or its directors. The auditor shall also answer questions raised by the shareholders, either at the meeting or in writing before the meeting, concerning his reports.

The directors may give a global answer to several questions on the same subject.